Sino Biopharmaceutical Limited
1177
Classement en actions
#1766
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Prix de l'action
$0.68180748
Capitalisation boursière
$12.14B
Changement (1 jour)
-1.30%
Changement (1 an)
-28.39%
Pays
HK
Échange Sino Biopharmaceutical Limited (1177)
Catégorie
Healthcare
Revenus pour Sino Biopharmaceutical Limited (1177)
Revenus en Jun 2026 TTM : $4.88B
Selon les derniers rapports financiers de Sino Biopharmaceutical Limited, le chiffre d'affaires actuel de l'entreprise (TTM) est de $4.88B. En 2023, l'entreprise a réalisé un chiffre d'affaires de $3.70B une diminution par rapport à le chiffre d'affaires de l'année 2022, qui était de $3.77B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Sino Biopharmaceutical Limited de 2000 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $4.88B | 23.50% |
| 2024 | $3.95B | 6.85% |
| 2023 | $3.70B | -1.90% |
| 2022 | $3.77B | -10.72% |
| 2021 | $4.23B | 16.75% |
| 2020 | $3.62B | 4.01% |
| 2019 | $3.48B | 14.60% |
| 2018 | $3.04B | 33.32% |
| 2017 | $2.28B | 11.60% |
| 2016 | $2.04B | 8.78% |
| 2015 | $1.88B | 17.41% |
| 2014 | $1.60B | 25.29% |
| 2013 | $1.28B | 18.63% |
| 2012 | $1.08B | 44.84% |
| 2011 | $742.34M | 40.70% |
| 2010 | $527.59M | 26.12% |
| 2009 | $418.31M | 42.04% |
| 2008 | $294.49M | 97.15% |
| 2007 | $149.37M | 58.30% |
| 2006 | $94.36M | -3.22% |
| 2005 | $97.50M | -27.90% |
| 2004 | $135.23M | 27.73% |
| 2003 | $105.87M | 19.26% |
| 2002 | $88.77M | 28.20% |
| 2001 | $69.24M | 37.37% |
| 2000 | $50.40M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $2.54B | -48.08% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $830.81M | -82.99% |
US
|
|
| - | - |
IT
|
